Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor
- 1 October 2002
- journal article
- Published by Springer Nature in Leukemia
- Vol. 16 (10) , 2027-2036
- https://doi.org/10.1038/sj.leu.2402674
Abstract
Leukemia is one of the leading journals in hematology and oncology. It is published monthly and covers all aspects of the research and treatment of leukemia and allied diseases. Studies of normal hemopoiesis are covered because of their comparative relevance.Keywords
This publication has 42 references indexed in Scilit:
- Differential function of STAT5 isoforms in head and neck cancer growth controlOncogene, 2002
- Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignanciesBlood, 2001
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- Flt3 Ligand Induces Tyrosine Phosphorylation of Gab1 and Gab2 and Their Association with Shp-2, Grb2, and PI3 KinaseBiochemical and Biophysical Research Communications, 2000
- Dissection of Signaling Cascades through gp130 In VivoImmunity, 2000
- Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemiaLeukemia, 1999
- Function and Signal Transduction Mediated by the Interleukin 3 Receptor System in HematopoiesisThe International Journal of Cell Cloning, 1996
- The VAV Family of Signal Transduction MoleculesCritical Reviews™ in Oncogenesis, 1996
- A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populationsCell, 1991
- Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitorsJournal of Medicinal Chemistry, 1989